Wyeth/Elan Submit Pharmacogenomics Study Report From Alzheimer’s Trial To FDA
This article was originally published in The Pink Sheet Daily
A gene expression study based on blood samples from a failed vaccine candidate trial could help develop other potential therapies, Wyeth says.
You may also be interested in...
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.
Emerging Company Profile: Dublin-based United Neuroscience, spun out of an animal vaccine maker, believes it can pick up and improve upon a vaccine approach to Alzheimer’s that was abandoned nearly two decades ago due to safety issues.
Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.